MS
KURA icon

Maven Securities’s Kura Oncology KURA Stock Holding History

Maven Securities’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-34,294
Closed -$480K – 1046
2021
Q4 		$480K Buy
+34,294
New +$556K 0.01% 569
2021
Q1 		– Sell
-14,000
Closed -$476K – 1235
2020
Q4 		$476K Buy
+14,000
New +$492K 0.05% 367

Other funds holding KURA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Maven Securities's KURA Position: Q1 2022 in Review

Maven Securities sold out of Kura Oncology (KURA) in Q1 2022, closing a stake of 34,294 shares — an estimated $480K sold.

Maven Securities first reported a position in KURA in Q4 2020 and held it in 2 quarters. The position peaked at $480K in Q4 2021. 152 funds tracked by Wall St. Rank hold KURA as of Q1 2022.

  • Maven Securities reported no remaining Kura Oncology position as of Q1 2022 after selling out during the quarter.
  • Maven Securities sold 34,294 Kura Oncology shares in Q1 2022, an estimated $480K.
  • Maven Securities first reported a position in Kura Oncology in Q4 2020 and held it in 2 quarters.
  • Maven Securities's Kura Oncology position peaked at $480K in Q4 2021.
  • 152 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2022.

Based on Maven Securities's 13F filing for Q1 2022, filed 16 May 2022.